News | November 10, 2025
Bristol Myers Squibb prices €5 billion senior unsecured notes offering
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Poviztra is a second brand of Wegovy
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Subscribe To Our Newsletter & Stay Updated
